Dean Pomerleau Posted January 22, 2016 Report Share Posted January 22, 2016 All, In another apparent micronutrient synergy involving DHA for improved brain health (see Curcumin Elevates DHA in the Brain thread for the other), this new randomized control trial  found that supplementing for two years with three B-vitamins (folic acid, B6 and B12) slowed the cognitive decline that often leads from mild cognitive impairment (MCI) to Alzheimer's Disease (AD), but only if the person had "high normal" levels of serum DHA at baseline: When omega-3 fatty acid concentrations are low, B vitamin treatment has no effect oncognitive decline in MCI, but when omega-3 levels are in the upper normal range,B vitamins interact to slow cognitive decline. A clinical trial of B vitaminscombined with omega-3 fatty acids is needed to see whether it is possible to slow the conversion from MCI to AD. Michael warns against CRers supplementing with DHA, but for brain health it seems that adequate DHA may be important. Curcumin might help increase DHA in the brain by boosting ALA->DHA conversion, but he's also dissed curcumin, so I'm wondering what he thinks of all this... --Dean ----------  J Alzheimers Dis. 2016 Jan 6. [Epub ahead of print] Omega-3 Fatty Acid Status Enhances the Prevention of Cognitive Declineby B Vitamins in Mild Cognitive Impairment. Oulhaj A(1), Jernerén F(2), Refsum H(2,)(3), David Smith A(2), de Jager CA(4). Free full text: http://content.iospress.com/articles/journal-of-alzheimers-disease/jad150777 A randomized trial (VITACOG) in people with mild cognitive impairment (MCI) foundthat B vitamin treatment to lower homocysteine slowed the rate of cognitive andclinical decline. We have used data from this trial to see whether baselineomega-3 fatty acid status interacts with the effects of B vitamin treatment. 266participants with MCI aged ≥70 years were randomized to B vitamins (folic acid,vitamins B6 and B12) or placebo for 2 years. Baseline cognitive test performance,clinical dementia rating (CDR) scale, and plasma concentrations of totalhomocysteine, total docosahexaenoic and eicosapentaenoic acids (omega-3 fattyacids) were measured. Final scores for verbal delayed recall, global cognition,and CDR sum-of-boxes were better in the B vitamin-treated group according toincreasing baseline concentrations of omega-3 fatty acids, whereas scores in theplacebo group were similar across these concentrations. Among those with goodomega-3 status, 33% of those on B vitamin treatment had global CDR scores >0compared with 59% among those on placebo. For all three outcome measures, higherconcentrations of docosahexaenoic acid alone significantly enhanced the cognitiveeffects of B vitamins, while eicosapentaenoic acid appeared less effective. Whenomega-3 fatty acid concentrations are low, B vitamin treatment has no effect oncognitive decline in MCI, but when omega-3 levels are in the upper normal range,B vitamins interact to slow cognitive decline. A clinical trial of B vitaminscombined with omega-3 fatty acids is needed to see whether it is possible to slowthe conversion from MCI to AD. PMID: 26757190 Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.